Versailles, France

Denis Marie Bernárd Chenebaux


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2006-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Denis Marie Bernard Chenebaux: Innovator in Infectious Disease Detection

Introduction

Denis Marie Bernard Chenebaux, based in Versailles, France, is an accomplished inventor known for his significant contributions to the field of medical diagnostics. With a notable patent to his name, he has made strides in the detection of infections caused by HIV-1 viruses, particularly group O.

Latest Patents

Chenebaux holds a patent for "Synthetic peptides useful in biological essays for detecting infections caused by group O HIV-1 viruses." This patent encompasses synthetic peptides that vary from 13 to 33 amino acids in length, either in a linear form or cyclized by means of inter-cysteine disulphide bridges. The specific formulations of these peptides include various biotinyl or amine functional groups and peptide sequences that enhance the sensitivity and reliability of detection tests for this particular strain of HIV.

Career Highlights

Denis Chenebaux currently works at Bio-Rad Pasteur, a renowned company in the field of biological research and diagnostics. His innovative work has contributed immensely to advancements in the detection of viral infections, reflecting his commitment to improving health outcomes.

Collaborations

Throughout his career, Chenebaux has collaborated with esteemed colleagues, including Jean-Francois Hubert Delagneau and Stephane Jean Xavier Gadelle. These partnerships have fostered an environment of innovation and shared knowledge, which has been crucial for developing cutting-edge diagnostic technologies.

Conclusion

Denis Marie Bernard Chenebaux exemplifies the spirit of innovation in medical science. His work not only showcases technical ingenuity but also has the potential to significantly impact public health through improved diagnostic methods for HIV-1 infections. As he continues his work at Bio-Rad Pasteur, the medical field looks forward to what other advancements he may bring forth in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…